Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease

Journal of Dairy Science

Volumn 97, Issue 12, 2014, Pages 7386-7393

  Nabavi, S ^a   Rafraf, M ^a   Somi, M H ^b   Homayouni Rad, A ^a   Asghari Jafarabadi, M ^a,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metabolic factor; Nonalcoholic fatty liver disease; Probiotic yogurt

Indexed keywords

BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS; LACTOBACILLUS ACIDOPHILUS;

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; TRIACYLGLYCEROL; YOGHURT;

ADULT; ANIMAL; BIFIDOBACTERIUM; BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LACTOBACILLUS ACIDOPHILUS; MALE; MICROBIOLOGY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ANIMALS; BIFIDOBACTERIUM; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS; TRIGLYCERIDES; YOGURT; YOUNG ADULT;

EID: 84919326883     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2014-8500     Document Type: Article

References (53)

1. Adibi A., Hekmatnia A., Shayganfar A. Ultrasound screening of nonalcoholic fatty liver in Isfahan Medical University personnel. Iran. J. Radiol. 2008, 5:1.
2. Aller R., De Luis D.A., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., De La Fuente B., Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15:1090-1095.
3. Anderson J.W., Gilliland S.E. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J. Am. Coll. Nutr. 1999, 18:43-50.
4. Ataie-Jafari A., Larijani B., Alavi Majd H., Tahbaz F. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann. Nutr. Metab. 2009, 54:22-27.
5. Baroutkoub A., Roushan Zamir M., Razmik B., Julayi H., Sohrabi Z., Mazloomi S.M., Eskandari M.H. Effects of probiotic yoghurt consumption on the serum cholesterol levels in hypercholesteremic cases in Shiraz, Southern Iran. Sci. Res. Essays 2010, 5:2206-2209.
6. Begley M., Hill C., Gahan C.G.M. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 2006, 72:1729-1738.
7. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:155-161. http://dx.doi.org/10.1159/000282080.
8. 1B Golden Syrian hamsters. PLoS ONE 2013, 8:e58394. http://dx.doi.org/10.1371/journal.pone.0058394.
9. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver Dis. 2012, 32:22-29. http://dx.doi.org/10.1055/s-0032-1306423.
10. Clark J.M., Brancati F., Diehl A. Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-1657. http://dx.doi.org/10.1053/gast.2002.33573.
11. Day, C. P. 2004. Non-alcoholic fatty liver disease. Pages 393-404 in Evidence-Based Gastroenterology.
12. Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A., Niafar M., Asghari-Jafarabadi M., Mofid V., Akbarian-Moghari A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J. Dairy Sci. 2011, 94:3288-3294. http://dx.doi.org/10.3168/jds.2010-4128.
13. Esposito E., Iacono A., Bianco G., Autore G., Cuzzocrea S., Vajro P., Canani R.B., Calignano A., Raso G.M., Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J. Nutr. 2009, 139:905-911. http://dx.doi.org/10.3945/jn.108.101808.
14. Fabian E., Elmadfa I. Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women. Ann. Nutr. Metab. 2006, 50:387-393.
15. FAO-WHO (Food and Agriculture Organization of the United Nations/World Health Organization). 2001. WHO Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Accessed Sep. 8, 2014. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf.
16. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
17. Gill H.K., Wu G.Y. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer?. World J. Gastroenterol. 2006, 12:345-353.
18. Goldin B.R., Gorbach S.L. Clinical indications for probiotics: an overview. Clin. Infect. Dis. 2008, 46(Suppl. 2):S96-S100. http://dx.doi.org/10.1086/523333.
19. Greany K.A., Bonorden M.J.L., Hamilton-Reeves J.M., McMullen M.H., Wangen K.E., Phipps W.R., Feirtag J., Thomas W., Kurzer M.S. Probiotic capsules do not lower plasma lipids in young women and men. Eur. J. Clin. Nutr. 2008, 62:232-237.
20. Hatakka K., Mutanen M., Holma R., Saxelin M., Korpela R. Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS administered in capsules is ineffective in lowering serum lipids. J. Am. Coll. Nutr. 2008, 27:441-447.
21. Homayouni A. Therapeutical Effects of Functional Probiotic, Prebiotic and Symbiotic Foods 2008, Tabriz University of Medical Sciences, Tabriz, Iran.
22. Karahan N., Işler M., Koyu A., Karahan A.G., Başyiğ it Kiliç G., Ciriş I.M., Sütçü R., Onaran I., Cam H., Keskin M. Effects of probiotics on methionine choline-deficient diet-induced steatohepatitis in rats. Turk. J. Gastroenterol. 2012, 23:110-121.
23. Kaur I.P., Kuhad A., Garg A., Chopra K. Probiotics: Delineation of prophylactic and therapeutic benefits. J. Med. Food 2009, 12:219-235. http://dx.doi.org/10.1089/jmf.2007.0544.
24. Kawase M., Hashimoto H., Hosoda M., Morita H., Hosono A. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J. Dairy Sci. 2000, 83:255-263.
25. Kiessling G., Schneider J., Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur. J. Clin. Nutr. 2002, 56:843-849.
26. Kneeman J.M., Misdraji J., Corey K.E. Secondary causes of nonalcoholic fatty liver disease. Therap. Adv. Gastroenterol. 2012, 5:199-207. http://dx.doi.org/10.1177/1756283X11430859.
27. Kumar M., Nagpal R., Kumar R., Hemalatha R., Verma V., Kumar A., Chakraborty C., Singh B., Marotta F., Jain Sh., Yadav H. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp. Diabetes Res. 2012, 2012:902917. http://dx.doi.org/10.1155/2012/902917.
28. Lata J., Jurankova J., Kopacova M., Vitek P. Probiotics in hepatology. World J. Gastroenterol. 2011, 17:2890-2896. http://dx.doi.org/10.3748/wjg.v17.i24.2890.
29. Lewis S.J., Burmeister S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur. J. Clin. Nutr. 2005, 59:776-780.
30. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., Desimone C., Song X.Y., Diehl A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
31. Loguercio C., De Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M., Cartenì M. Gut-liver axis: A new point of attack to treat chronic liver damage?. Am. J. Gastroenterol. 2002, 97:2144-2146.
32. Lomonaco R., Sunny N.E., Brill F., Cusi K. Nonalcoholic fatty liver disease: Current issues and novel treatment approaches. Drugs 2013, 73:1-14. http://dx.doi.org/10.1007/s40265-012-0004-0.
33. Lye H.S., Kuan C.Y., Ewe J.A., Fung W.Y., Liong M.T. The improvement of hypertension by probiotics: Effects on cholesterol, diabetes, renin, and phytoestrogens. Int. J. Mol. Sci. 2009, 10:3755-3775. http://dx.doi.org/10.3390/ijms10093755.
34. Malaguarnera M., Greco F., Barone G., Gargante M.P., Malaguarnera M., Toscano M.A. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: A randomized, double-blind, placebo controlled study. Dig. Dis. Sci. 2007, 52:3259-3265.
35. Malaguarnera M., Vacante M., Antic T., Giordano M., Chisari G., Acquaviva R., Mastrojeni S., Malaguarnera G., Mistretta A., Li Volti G., Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57:545-553. http://dx.doi.org/10.1007/s10620-011-1887-4.
36. Metchnikoff, I. I. 1907. The Prolongation of Life: Optimistic Studies. Translated and edited by P. Chalmers Mitchell. Heinemann, London, UK. Reprinted (2004) by Springer Publishing Co., New York, NY.
37. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 2004, 8:613-618.
38. Naruszewicz M., Johansson M.L., Zapolska-Downar D., Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 2002, 76:1249-1255.
39. Nguyen T.D., Kang J.H., Lee M.S. Characterization of Lactobacillus plantarumph04, a potential probiotic bacterium with cholesterol-lowering effects. Int. J. Food Microbiol. 2007, 113:358-361.
40. Niazmand R., Niazmand A., Sarabi M., Arabporiani N., Doaei A. Effect of bioyogurt consumption on fatty metabolites of serum and colonic microflora in healthy subjects. J. Agric. Sci. Technol. 2010, 12:597-603.
41. Ooi L.-G., Liong M.-T. Cholesterol-lowering effects of probiotics and prebiotics: A review of in vivo and in vitro findings. Int. J. Mol. Sci. 2010, 11:2499-2522. http://dx.doi.org/10.3390/ijms11062499.
42. Paik H.D., Park J.-S., Park E. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet. Biol. Pharm. Bull. 2005, 28:1270-1274.
43. Pocock S.J. Clinical Trials: A Practical Approach 1983, John Wiley & Sons, New York, NY.
44. Rafiq N., Younossi Z. Nonalcoholic fatty liver disease: A practical approach to evaluation and management. Clin. Liver Dis. 2009, 13:249-266. http://dx.doi.org/10.1016/j.cld.2009.02.009.
45. Roberts E.A. Non-alcoholic fatty liver disease (NAFLD) in children. Front. Biosci. 2005, 10:2306-2318.
46. Sadrzadeh-Yeganeh H., Elmadfa I., Djazayery A., Jalali M., Heshmat R., Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. Br. J. Nutr. 2010, 103:1778-1783. http://dx.doi.org/10.1017/S0007114509993801.
47. Viana J.V., Da Cruz A.G., Zoellner S.S., Silva R., Batista A.L.D. Probiotic foods: Consumer perception and attitudes. Int. J. Food Sci. Technol. 2007, 43:1577-1580. http://dx.doi.org/10.1111/j.1365-2621.2007.01596-x.
48. Wang Y., Xu N., Xi A., Ahmed Z., Zhang B., Bai X. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl. Microbiol. Biotechnol. 2009, 84:341-347. http://dx.doi.org/10.1007/s00253-009-2012-x.
49. Wong V. Recent advances in the management of nonalcoholic fatty liver disease. Med. Bull. 2008, 13:19-22.
50. Xiao J.Z., Kondo S., Takahashi N., Miyaji K., Oshida K., Hiramatsu A., Iwatsuki K., Kokubo S., Hosono A. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J. Dairy Sci. 2003, 86:2452-2461.
51. Yadav H., Jain S., Sinha P.R. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J. Dairy Res. 2008, 75:189-195. http://dx.doi.org/10.1017/S0022029908003129.
52. Zar J.H. Biostatistical Analysis 1998, Pearson Press, New York, NY.
53. Zhuang G., Liu X.-M., Zhang Q.-X., Tian F.-W., Zhang H., Zhang H.-P., Chen W. Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics. Clin. Lipidol. 2012, 7:501-507. http://dx.doi.org/10.2217/clp.12.40.